天士力2025年每股收益预增15.63%，提高投资者回报

Group 1 - The core theme of the current capital market is the protection of investors' rights, with recent initiatives from the China Securities Regulatory Commission and the Shanghai Stock Exchange emphasizing high-quality development as the best return for investors [1][2] - During the "14th Five-Year Plan" period, listed companies distributed a total of 10.6 trillion yuan to investors, representing an increase of over 80% compared to the previous five-year period, which is 2.07 times the amount raised through IPOs and refinancing [2] - Tianjin Tasly Pharmaceutical's performance forecast indicates an expected net profit of 1.105 billion yuan for 2025, a year-on-year increase of 15.68%, and basic earnings per share of 0.74 yuan, reflecting the company's commitment to high-quality development and improved investor returns [2] Group 2 - Tianjin Tasly is actively integrating with China Resources Sanjiu, focusing on "value reshaping," "business reshaping," "organizational reshaping," and "spiritual reshaping" to enhance its management system [3] - The company is optimizing its operations and management while leveraging the resources of China Resources to enhance its competitive advantage [3] - In the marketing sector, the company is collaborating with China Resources to innovate retail models and strengthen strategic partnerships with leading pharmacy chains [4]